Eribaxaban
Eribaxaban is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
11 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | HP_0000939 | M81.0 | — | — | — | 1 | — | 1 |
| Bone fractures | D050723 | EFO_0003931 | T14.8 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 1 | 3 | — | — | — | 3 |
| Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
| Neoplasms | D009369 | — | C80 | — | 2 | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | — | 2 | — | — | — | 2 |
| Lymphoma | D008223 | — | C85.9 | — | 2 | — | — | — | 2 |
| Neuroblastoma | D009447 | EFO_0000621 | — | — | 2 | — | — | — | 2 |
| Glioma | D005910 | EFO_0000520 | — | — | 2 | — | — | — | 2 |
| Osteosarcoma | D012516 | — | — | — | 2 | — | — | — | 2 |
| Germ cell and embryonal neoplasms | D009373 | — | — | — | 2 | — | — | — | 2 |
| Medulloblastoma | D008527 | — | — | — | 2 | — | — | — | 2 |
Show 23 more
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | — | — | — | 2 | 2 |
| Aortic dissection | D000784 | — | I71.0 | — | — | — | — | 1 | 1 |
| Small cell lung carcinoma | D055752 | — | — | — | — | — | — | 1 | 1 |
| Colonic neoplasms | D003110 | — | C18 | — | — | — | — | 1 | 1 |
| Colonic polyps | D003111 | — | K63.5 | — | — | — | — | 1 | 1 |
| Adenoma | D000236 | — | — | — | — | — | — | 1 | 1 |
| Colonoscopy | D003113 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Eribaxaban |
| INN | eribaxaban |
| Description | Eribaxaban is a member of the class of pyrrolidines that is (2R,4R)-N(1)-(p-chlorophenyl)-4-methoxypyrrolidine-1,2-dicarboxamide in which the nitrogen of the 2-carbamoyl group has been substituted by a 2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl group. It is a synthetic organic anticoagulant compound that targets activated factor Xa in the coagulation cascade. It has a role as an anticoagulant, an EC 3.4.21.6 (coagulation factor Xa) inhibitor and a serine protease inhibitor. It is a pyridone, a secondary carboxamide, a member of ureas, a member of monochlorobenzenes, a member of pyrrolidines and a member of monofluorobenzenes. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CO[C@@H]1C[C@H](C(=O)Nc2ccc(-n3ccccc3=O)cc2F)N(C(=O)Nc2ccc(Cl)cc2)C1 |
Identifiers
| PDB | — |
| CAS-ID | 536748-46-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL476186 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06920 |
| UNII ID | 5FCH6YDY7Z (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 167,988 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use